AAGL Practice Report: Practice Guidelines for the Diagnosis and Management of Submucous Leiomyomas

Journal of Minimally Invasive Gynecology

Volumn 19, Issue 2, 2012, Pages 152-171

[No Author Info available]

Author keywords

Abnormal uterine bleeding; Abortion; Fibroid; Heavy menstrual bleeding; Hysteroscopy; Infertility; Leiomyoma; Menorrhagia; Myoma; Myomectomy; Pregnancy loss; Submucosal; Submucous; Uterine artery embolization

Indexed keywords

CARBOPROST; DANAZOL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ARTERY OCCLUSION; ARTICLE; BALLOON CATHETER; BURN; CONSENSUS; FEMALE FERTILITY; HISTOGENESIS; HUMAN; HYSTERECTOMY; LEIOMYOMA; MYOMECTOMY; PATHOGENESIS; PATIENT CARE; PATIENT COUNSELING; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREGNANCY DISORDER; SUBMUCOUS LEIOMYOMA; UTERINE ARTERY EMBOLIZATION; UTERUS BLEEDING; UTERUS MYOMA;

ABORTION, SPONTANEOUS; ENDOMETRIUM; FEMALE; HUMANS; HYSTEROSCOPY; INFERTILITY, FEMALE; LAPAROSCOPY; LEIOMYOMA; MENORRHAGIA; MYOMETRIUM; PREGNANCY; UTERINE ARTERY EMBOLIZATION; UTERINE NEOPLASMS;

EID: 84857622049     PISSN: 15534650     EISSN: 15534669     Source Type: Journal    
DOI: 10.1016/j.jmig.2011.09.005     Document Type: Article

References (167)

1. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979, 121:1193-1254. The periodic health examination.
2. Day Baird D., Dunson D.B., Hill M.C., Cousins D., Schectman J.M. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188:100-107. (P).
3. Borgfeldt C., Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta Obstet Gynecol Scand 2000, 79:202-207. (II-2).
4. Whiteman M.K., Hillis S.D., Jamieson D.J., et al. Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol 2008, 198. 34 e1-e7 (II-2).
5. Marugo M., Centonze M., Bernasconi D., Fazzuoli L., Berta S., Giordano G. Estrogen and progesterone receptors in uterine leiomyomas. Acta Obstet Gynecol Scand 1989, 68:731-735. (N/A).
6. Brosens I., Deprest J., Dal Cin P., Van den Berghe H. Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 1998, 69:232-235. (II-1).
7. Brosens J., Campo R., Gordts S., Brosens I. Submucous and outer myometrium leiomyomas are two distinct clinical entities. Fertil Steril 2003, 79:1452-1454. (R).
8. Wamsteker K., Emanuel M.H., de Kruif J.H. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993, 82:736-740. (II-2).
9. Munro M.G., Critchley H.O., Broder M.S., Fraser I.S. The FIGO Classification System (" PALM-COEIN" ) for causes of abnormal uterine bleeding in non-gravid women in the reproductive years, including guidelines for clinical investigation. Int J Gynaecol Obstet 2011, 113:3-13. (N/A).
10. Lasmar R.B., Barrozo P.R., Dias R., Oliveira M.A. Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment-preliminary report. J Minim Invasive Gynecol 2005, 12:308-311. (II-2).
11. Vercellini P., Zaina B., Yaylayan L., Pisacreta A., De Giorgi O., Crosignani P.G. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol 1999, 94:341-347. (II-2).
12. Fraser I.S., Critchley H.O., Munro M.G., Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007, 87:466-476. (N/A).
13. Parker W.H., Fu Y.S., Berek J.S. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994, 83:414-418. (P).
14. Leibsohn S., d'Ablaing G., Mishell D.R., Schlaerth J.B. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990, 162:968-974. discussion 74-76. (P).
15. Vilos G.A., Harding P.G., Sugimoto A.K., Ettler H.C., Bernier M.J. Hysteroscopic endomyometrial resection of three uterine sarcomas. J Am Assoc Gynecol Laparosc 2001, 8:545-551. (III).
16. Vilos G.A., Edris F., Abu-Rafea B., Hollett-Caines J., Ettler H.C., Al-Mubarak A. Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery. J Minim Invasive Gynecol 2009, 16:318-325. (III).
17. van Dongen H., de Kroon C.D., Jacobi C.E., Trimbos J.B., Jansen F.W. Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2007, 114:664-675. (SR).
18. Emanuel M.H., Verdel M.J.C., Stas H., et al. An audit of true prevalence of intrauterine pathology: the hysteroscopical findings controlled the patient selection in 1202 patients with abnormal uterine bleeding. Gynaecol Endosc 1995, 4:237-241. (P).
19. Lasmar R.B., Dias R., Barrozo P.R., Oliveira M.A., Coutinho Eda S., da Rosa D.B. Prevalence of hysteroscopic findings and histologic diagnoses in patients with abnormal uterine bleeding. Fertil Steril 2008, 89:1803-1807. (P).
20. Indman P.D. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol 1993, 81:716-720. (II-2).
21. Polena V., Mergui J.L., Perrot N., Poncelet C., Barranger E., Uzan S. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007, 130:232-237. (II-2).
22. Emanuel M.H., Wamsteker K., Hart A.A., Metz G., Lammes F.B. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol 1999, 93:743-748. (II-2).
23. Fernandez H., Sefrioui O., Virelizier C., Gervaise A., Gomel V., Frydman R. Hysteroscopic resection of submucosal myomas in patients with infertility. Hum Reprod 2001, 16:1489-1492. (II-2).
24. Buttram V.C., Reiter R.C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981, 36:433-445. (R).
25. Verkauf B.S. Myomectomy for fertility enhancement and preservation. Fertil Steril 1992, 58:1-15. (R).
26. Donnez J., Jadoul P. What are the implications of myomas on fertility? A need for a debate?. Hum Reprod 2002, 17:1424-1430. (III).
27. Pritts E.A., Parker W.H., Olive D.L. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009, 91:1215-1223. (SR).
28. Varasteh N.N., Neuwirth R.S., Levin B., Keltz M.D. Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Obstet Gynecol 1999, 94:168-171. (II-2).
29. Bernard G., Darai E., Poncelet C., Benifla J.L., Madelenat P. Fertility after hysteroscopic myomectomy: effect of intramural myomas associated. Eur J Obstet Gynecol Reprod Biol 2000, 88:85-90. (II-3).
30. Surrey E.S., Lietz A.K., Schoolcraft W.B. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril 2001, 75:405-410. (II-3).
31. Surrey E.S., Minjarez D.A., Stevens J.M., Schoolcraft W.B. Effect of myomectomy on the outcome of assisted reproductive technologies. Fertil Steril 2005, 83:1473-1479. (II-2).
32. Shokeir T., El-Shafei M., Yousef H., Allam A.F., Sadek E. Submucous myomas and their implications in the pregnancy rates of patients with otherwise unexplained primary infertility undergoing hysteroscopic myomectomy: a randomized matched control study. Fertil Steril 2010, 94:724-729. (I).
33. Rackow B.W., Taylor H.S. Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity. Fertil Steril 2010, 93:2027-2034. (L).
34. Klatsky P.C., Tran N.D., Caughey A.B., Fujimoto V.Y. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008, 198:357-366. (SR).
35. Deligdish L., Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970, 23:676-680. (L).
36. Maguire M., Segars J.H. Benign uterine disease: leiomyomata and benign polyps. The endometrium: molecular, cellular and clinical perspectives 2008, Informa Health Care, London, (R). 2nd ed. J.D. Aplin, A.T. Fazleabas, S.R. Glasser, L.C. Giudice (Eds.).
37. Golan A., Eilat E., Ron-El R., Herman A., Soffer Y., Bukovsky I. Hysteroscopy is superior to hysterosalpingography in infertility investigation. Acta Obstet Gynecol Scand 1996, 75:654-656. (II-2).
38. Preutthipan S., Linasmita V. A prospective comparative study between hysterosalpingography and hysteroscopy in the detection of intrauterine pathology in patients with infertility. J Obstet Gynaecol Res 2003, 29:33-37. (II-1).
39. Roma Dalfo A., Ubeda B., Ubeda A., et al. Diagnostic value of hysterosalpingography in the detection of intrauterine abnormalities: a comparison with hysteroscopy. AJR Am J Roentgenol 2004, 183:1405-1409. (II-2).
40. Farquhar C., Ekeroma A., Furness S., Arroll B. A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women. Acta Obstet Gynecol Scand 2003, 82:493-504. (SR).
41. Dueholm M., Lundorf E., Hansen E.S., Ledertoug S., Olesen F. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002, 186:409-415. (II-1).
42. Dueholm M., Lundorf E., Hansen E.S., Ledertoug S., Olesen F. Evaluation of the uterine cavity with magnetic resonance imaging, transvaginal sonography, hysterosonographic examination, and diagnostic hysteroscopy. Fertil Steril 2001, 76:350-357. (II-1).
43. Dueholm M., Lundorf E., Sorensen J.S., Ledertoug S., Olesen F., Laursen H. Reproducibility of evaluation of the uterus by transvaginal sonography, hysterosonographic examination, hysteroscopy and magnetic resonance imaging. Human Reprod 2002, 17:195-200. (II-1).
44. Dueholm M., Lundorf E., Hansen E.S., Sorensen J.S., Ledertoug S., Olesen F. Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis. Fertil Steril 2001, 76:588-594. (II-1).
45. Ross R.K., Pike M.C., Vessey M.P., Bull D., Yeates D., Casagrande J.T. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986, 293:359-362. (II-2).
46. Marshall L.M., Spiegelman D., Goldman M.B., et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998, 70:432-439. (II-2).
47. Chiaffarino F., Parazzini F., La Vecchia C., Marsico S., Surace M., Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999, 106:857-860. (II-2).
48. Sharafi K., Junze K., Nosher J.L., Bachmann G.A. Symptomatic fibroids: the need to include low dose OCP's as a treatment option. Prim Care Update Obstet/Gynecol 2000, 7:46-48. (R).
49. Sivin I., Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994, 61:70-77. (I).
50. Magalhaes J., Aldrighi J.M., de Lima G.R. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007, 75:193-198. (II-2).
51. Lumbiganon P., Rugpao S., Phandhu-fung S., Laopaiboon M., Vudhikamraksa N., Werawatakul Y. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study. Br J Obstet Gynaecol 1996, 103:909-914. (II-2).
52. Mavrelos D., Ben-Nagi J., Holland T., Hoo W., Naftalin J., Jurkovic D. The natural history of fibroids. Ultrasound Obstet Gynecol 2010, 35:238-242. (II-2).
53. DeWaay D.J., Syrop C.H., Nygaard I.E., Davis W.A., Van Voorhis B.J. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002, 100:3-7. (II-2).
54. Peddada S.D., Laughlin S.K., Miner K., et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 2008, 105:19887-19892. (II-2).
55. Tropeano G., Amoroso S., Scambia G. Non-surgical management of uterine fibroids. Hum Reprod Update 2008, 14:259-274. (R).
56. Soysal S., Soysal M.E. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005, 59:29-35. (II-2).
57. Zapata L.B., Whiteman M.K., Tepper N.K., Jamieson D.J., Marchbanks P.A., Curtis K.M. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010, 82:41-55. (SR).
58. Lukes A.S., Moore K.A., Muse K.N., et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010, 116:865-875. (I).
59. Friedman A.J., Hoffman D.I., Comite F., Browneller R.W., Miller J.D. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991, 77:720-725. (I).
60. Fiscella K., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006, 108:1381-1387. (I).
61. Carbonell Esteve J.L., Acosta R., Heredia B., Perez Y., Castaneda M.C., Hernandez A.V. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008, 112:1029-1036. (I).
62. Parsanezhad M.E., Azmoon M., Alborzi S., et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010, 93:192-198. (I).
63. Stovall T.G., Muneyyirci-Delale O., Summitt R.L., Scialli A.R. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995, 86:65-71. (I).
64. Palomba S., Affinito P., Di Carlo C., Bifulco G., Nappi C. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. Fertil Steril 1999, 72:889-895. (II-2).
65. Scialli A.R., Levi A.J. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril 2000, 74:540-546. (II-2).
66. Hald K., Klow N.E., Qvigstad E., Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol 2007, 109:20-27. (I).
67. Vilos G.A., Vilos E.C., Romano W., Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: case report. Hum Reprod 2006, 21:269-271. (III).
68. Hald K., Klow N.E., Qvigstad E., Istre O. Treatment of uterine myomas with transvaginal uterine artery occlusion: possibilities and limitations. J Minim Invasive Gynecol 2008, 15:631-635. (II-3).
69. Gupta J.K., Sinha A.S., Lumsden M.A., Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2006, CD005073. (SR).
70. Goodwin S.C., Spies J.B., Worthington-Kirsch R., et al. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol 2008, 111:22-33. (II-2).
71. Spies J.B., Spector A., Roth A.R., Baker C.M., Mauro L., Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002, 100:873-880. (II-3).
72. Al-Fozan H., Tulandi T. Factors affecting early surgical intervention after uterine artery embolization. Obstet Gynecol Surv 2002, 57:810-815. (II-2).
73. Mehta H., Sandhu C., Matson M., Belli A.M. Review of readmissions due to complications from uterine fibroid embolization. Clin Radiol 2002, 57:1122-1124. (II-2).
74. Ravina J.H., Aymard A., Ciraru-Vigneron N., et al. Uterine fibroid embolization: results from 454 cases (Fr). Gynecol Obstet Fertil 2003, 31:597-605. (II-3).
75. Park A.J., Bohrer J.C., Bradley L.D., et al. Incidence and risk factors for surgical intervention after uterine artery embolization. Am J Obstet Gynecol 2008, 199:671.e1-671.e6. (II-3).
76. Radeleff B., Eiers M., Bellemann N., et al. Expulsion of dominant submucosal fibroids after uterine artery embolization. Eur J Radiol 2010, 75:e57-e63. (II-2).
77. Verma S.K., Bergin D., Gonsalves C.F., Mitchell D.G., Lev-Toaff A.S., Parker L. Submucosal fibroids becoming endocavitary following uterine artery embolization: risk assessment by MRI. AJR Am J Roentgenol 2008, 190:1220-1226. (II-2).
78. Walker W.J., Carpenter T.T., Kent A.S. Persistent vaginal discharge after uterine artery embolization for fibroid tumors: cause of the condition, magnetic resonance imaging appearance, and surgical treatment. Am J Obstet Gynecol 2004, 190:1230-1233. (II-3).
79. Homer H., Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010, 94:324-330. (SR).
80. Phillips D.R., Milim S.J., Nathanson H.G., Haselkorn J.S. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc 1997, 4:425-433. (II-3).
81. Bergamini V., Ghezzi F., Cromi A., et al. Laparoscopic radiofrequency thermal ablation: a new approach to symptomatic uterine myomas. Am J Obstet Gynecol 2005, 192:768-773. (II-3).
82. Ghezzi F., Cromi A., Bergamini V., Scarperi S., Bolis P., Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc 2007, 21:2081-2085. (II-3).
83. Cho H.H., Kim J.H., Kim M.R. Transvaginal radiofrequency thermal ablation: a day-care approach to symptomatic uterine myomas. Aust N Z J Obstet Gynaecol 2008, 48:296-301. (II-3).
84. Nisolle M., Smets M., Malvaux V., Anaf V., Donnez J. Laparoscopic myolysis with the Nd:YAG laser. J Gynecol Surg 1993, 9:95-99. (II-3).
85. Zupi E., Marconi D., Sbracia M., et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: one-year follow up. J Minim Invasive Gynecol 2005, 12:343-346. (II-3).
86. Pansky M., Cowan B.D., Frank M., Hampton H.L., Zimberg S. Laparoscopically assisted uterine fibroid cryoablation. Am J Obstet Gynecol 2009, 201:571.e1-571.e7. (II-3).
87. Kanaoka Y., Yoshida C., Fukuda T., Kajitani K., Ishiko O. Transcervical microwave myolysis for uterine myomas assisted by transvaginal ultrasonic guidance. J Obstet Gynaecol Res 2009, 35:145-151. (II-3).
88. Stewart E.A., Rabinovici J., Tempany C.M., et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006, 85:22-29. (II-3).
89. Funaki K., Fukunishi H., Funaki T., Kawakami C. Mid-term outcome of magnetic resonance-guided focused ultrasound surgery for uterine myomas: from six to twelve months after volume reduction. J Minim Invasive Gynecol 2007, 14:616-621. (II-3).
90. Taran F.A., Tempany C.M., Regan L., Inbar Y., Revel A., Stewart E.A. Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas. Ultrasound Obstet Gynecol 2009, 34:572-578. (II-1).
91. Hindly J., Gedroyc W.M., Regan L., et al. Guidance of focused ultrasound therapy of uterine fibroids: early results. Am J Roentgenol 2002, 183:1713-1719. (II-3).
92. Soysal M.E., Soysal S.K., Vicdan K. Thermal balloon ablation in myoma-induced menorrhagia under local anesthesia. Gynecol Obstet Invest 2001, 51:128-133. (I).
93. Sabbah R., Desaulniers G. Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study. J Minim Invasive Gynecol 2006, 13:467-471. (II-2).
94. Glasser M.H., Zimmerman J.D. The HydroThermAblator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc 2003, 10:521-557. (II-3).
95. The HTA system for management of menorrhagia in women with myomas: 6- to 12-month follow-up. J Minim Invasive Gynecol 2005, 12:s-60. Mba E, (II-3).
96. Rosenbaum S.P., Fried M., Munro M.G. Endometrial hydrothermablation: a comparison of short-term clinical effectiveness in patients with normal endometrial cavities and those with intracavitary pathology. J Minim Invasive Gynecol 2005, 12:144-149. (II-2).
97. Glasser M.H., Heinlein P.K., Hung Y.Y. Office endometrial ablation with local anesthesia using the HydroThermAblator system: Comparison of outcomes in patients with submucous myomas with those with normal cavities in 246 cases performed over 5(1/2) years. J Minim Invasive Gynecol 2009, 16:700-707. (II-2).
98. Cooper J.M., Anderson T.L., Fortin C.A., Jack S.A., Plentl M.B. Microwave endometrial ablation vs. rollerball electroablation for menorrhagia: a multicenter randomized trial. J Am Assoc Gynecol Laparosc 2004, 11:394-403. (I).
99. Kanaoka Y., Hirai K., Ishiko O. Microwave endometrial ablation for menorrhagia caused by large submucous myomas. J Obstet Gynaecol Res 2005, 31:565-570. (III).
100. Jin C., Hu Y., Chen X.C., Zheng F.Y., Lin F., Zhou K., et al. Laparoscopic versus open myomectomy-a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2009, 145:14-21. (SR).
101. Nezhat C., Lavie O., Hsu S., Watson J., Barnett O., Lemyre M. Robotic-assisted laparoscopic myomectomy compared with standard laparoscopic myomectomy-a retrospective matched control study. Fertil Steril 2009, 91:556-559. (II-2).
102. Bedient C.E., Magrina J.F., Noble B.N., Kho R.M. Comparison of robotic and laparoscopic myomectomy. Am J Obstet Gynecol 2009, 201:566.e1-566.e5. (III).
103. Kho K.A., Nezhat C. Parasitic myomas. Obstet Gynecol 2009, 114:611-615. (III).
104. Larrain D., Rabischong B., Khoo C.K., Botchorishvili R., Canis M., Mage G. " Iatrogenic" parasitic myomas: unusual late complication of laparoscopic morcellation procedures. J Minim Invasive Gynecol 2010, 17:719-724. (III).
105. Cucinella G., Granese R., Calagna G., Somigliana E., Perino A. Parasitic myomas after laparoscopic surgery: an emerging complication in the use of morcellator? Description of four cases. Fertil Steril 2011, 96:e90-e96. (III).
106. Goldrath M.H. Vaginal removal of the pedunculated submucous myoma. Historical observations and development of a new procedure. J Reprod Med 1990, 35:921-924. (II-3).
107. Neuwirth R.S., Amin H.K. Excision of submucus fibroids with hysteroscopic control. Am J Obstet Gynecol 1976, 126:95-99. (III).
108. Derman S.G., Rehnstrom J., Neuwirth R.S. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991, 77:591-594. (II-3).
109. Hart R., Molnar B.G., Magos A. Long-term follow-up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol 1999, 106:700-705. (II-3).
110. Loffer F.D. Improving results of hysteroscopic submucosal myomectomy for menorrhagia by concomitant endometrial ablation. J Minim Invasive Gynecol 2005, 12:254-260. (II-3).
111. Rovio P.H., Helin R., Heinonen P.K. Long-term outcome of hysteroscopic endometrial resection with or without myomectomy in patients with menorrhagia. Arch Gynecol Obstet 2009, 279:159-163. (II-2).
112. Stovall T.G., Ling F.W., Henry L.C., Woodruff M.R. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991, 164:1420-1423. discussion 3-5. (I).
113. Donnez J., Schrurs B., Gillerot S., Sandow J., Clerckx F. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989, 51:947-950. (II-3).
114. Campo S., Campo V., Gambadauro P. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premenopausal women. Acta Obstet Gynecol Scand 2005, 84:756-760. (II-2).
115. Mavrelos D., Ben-Nagi J., Davies A., Lee C., Salim R., Jurkovic D. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial. Hum Reprod 2010, 25:2264-2269. (I).
116. Muzii L., Boni T., Bellati F., et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study. Fertil Steril 2010, 94:1496-1499. (I).
117. Kapp N., Lohr P.A., Ngo T.D., Hayes J.L. Cervical preparation for first trimester surgical abortion. Cochrane Database Syst Rev 2010, CD007207. (SR).
118. Darwish A.M., Ahmad A.M., Mohammad A.M. Cervical priming prior to operative hysteroscopy: a randomized comparison of laminaria versus misoprostol. Hum Reprod 2004, 19:2391-2394. (I).
119. Lin Y.H., Hwang J.L., Seow K.M., Huang L.W., Chen H.J., Hsieh B.C. Laminaria tent vs misoprostol for cervical priming before hysteroscopy: Randomized study. J Minim Invasive Gynecol 2009, 16:708-712. (I).
120. Preutthipan S., Herabutya Y. A randomized controlled trial of vaginal misoprostol for cervical priming before hysteroscopy. Obstet Gynecol 1999, 94:427-430. (I).
121. Preutthipan S., Herabutya Y. Vaginal misoprostol for cervical priming before operative hysteroscopy: a randomized controlled trial. Obstet Gynecol 2000, 96:890-894. (I).
122. Ngai S.W., Chan Y.M., Ho P.C. The use of misoprostol prior to hysteroscopy in postmenopausal women. Hum Reprod 2001, 16:1486-1488. (I).
123. Thomas J.A., Leyland N., Durand N., Windrim R.C. The use of oral misoprostol as a cervical ripening agent in operative hysteroscopy: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 2002, 186:876-879. (I).
124. Barcaite E., Bartusevicius A., Railaite D.R., Nadisauskiene R. Vaginal misoprostol for cervical priming before hysteroscopy in perimenopausal and postmenopausal women. Int J Gynaecol Obstet 2005, 91:141-145. (I).
125. Crane J.M., Healey S. Use of misoprostol before hysteroscopy: a systematic review. J Obstet Gynaecol Can 2006, 28:373-379. (SR).
126. Uckuyu A., Ozcimen E.E., Sevinc F.C., Zeyneloglu H.B. Efficacy of vaginal misoprostol before hysteroscopy for cervical priming in patients who have undergone cesarean section and no vaginal deliveries. J Minim Invasive Gynecol 2008, 15:472-475. (I).
127. Batukan C., Ozgun M.T., Ozcelik B., Aygen E., Sahin Y., Turkyilmaz C. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol. Fertil Steril 2008, 89:966-973. (I).
128. Oppegaard K.S., Lieng M., Berg A., Istre O., Qvigstad E., Nesheim B.I. A combination of misoprostol and estradiol for preoperative cervical ripening in postmenopausal women: a randomised controlled trial. BJOG 2010, 117:53-61. (I).
129. Phillips D.R., Nathanson H.G., Milim S.J., Haselkorn J.S. The effect of dilute vasopressin solution on the force needed for cervical dilatation: a randomized controlled trial. Obstet Gynecol 1997, 89:507-511. (I).
130. Aydeniz B., Gruber I.V., Schauf B., Kurek R., Meyer A., Wallwiener D. A multicenter survey of complications associated with 21,676 operative hysteroscopies. Eur J Obstet Gynecol Reprod Biol 2002, 104:160-164. (II-2).
131. Agostini A., Cravello L., Shojai R., Ronda I., Roger V., Blanc B. Postoperative infection and surgical hysteroscopy. Fertil Steril 2002, 77:766-768. (II-2).
132. McCausland V.M., Fields G.A., McCausland A.M., Townsend D.E. Tuboovarian abscesses after operative hysteroscopy. J Reprod Med 1993, 38:198-200. (III).
133. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009, 113:1180-1189. (N/A).
134. Makris N., Vomvolaki E., Mantzaris G., Kalmantis K., Hatzipappas J., Antsaklis A. Role of a bipolar resectoscope in subfertile women with submucous myomas and menstrual disorders. J Obstet Gynaecol Res 2007, 33:849-854. (II-3).
135. Mencaglia L., Lugo E., Consigli S., Barbosa C. Bipolar resectoscope: the future perspective of hysteroscopic surgery. Gynaecolgic Surg 2009, 6:15-20. (III).
136. Touboul C., Fernandez H., Deffieux X., Berry R., Frydman R., Gervaise A. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertil Steril 2009, 92:1690-1693. (II-3).
137. Darwish A.M., Hassan Z.Z., Attia A.M., Abdelraheem S.S., Ahmed Y.M. Biological effects of distension media in bipolar versus monopolar resectoscopic myomectomy: a randomized trial. J Obstet Gynaecol Res 2010, 36:810-817. (I).
138. Emanuel M.H., Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005, 12:62-66. (III).
139. Indman P.D., Soderstrom R.M. Depth of endometrial coagulation with the urologic resectoscope. J Reprod Med 1990, 35:633-635. (L).
140. Clark T.J., Mahajan D., Sunder P., Gupta J.K. Hysteroscopic treatment of symptomatic submucous fibroids using a bipolar intrauterine system: a feasibility study. Eur J Obstet Gynecol Reprod Biol 2002, 100:237-242. (III).
141. Bettocchi S., Nappi L., Ceci O., et al. Treatment of submucosal and partially intramural myomas using the bipolar Versapoint system. J Am Assoc Gynecol Laparosc 2004, 11:s-17-s-18. (II-3).
142. Brooks P.G. Resectoscopic myoma vaporizer. J Reprod Med 1995, 40:791-795. (III).
143. Vercellini P., Oldani S., Yaylayan L., Zaina B., De Giorgi O., Crosignani P.G. Randomized comparison of vaporizing electrode and cutting loop for endometrial ablation. Obstet Gynecol 1999, 94:521-527. (I).
144. Vercellini P., Oldani S., Milesi M., Rossi M., Carinelli S., Crosignani P.G. Endometrial ablation with a vaporizing electrode. I. Evaluation of in vivo effects. Acta Obstet Gynecol Scand 1998, 77:683-687. (L).
145. Vercellini P., Oldani S., DeGiorgi O., Cortesi, Moschetta M., Crosignani P.G. Endometrial Ablation with a Vaporizing Electrode in Women with Regular Uterine Cavity or Submucous Leiomyomas. J Am Assoc Gynecol Laparosc 1996, 3:S52. (II-2).
146. Vilos G.A. Dispersive Pad Injuries Associated with Hysteroscopic Surgery. J Am Assoc Gynecol Laparosc 1999, 6:364-367. (III).
147. van Dongen H., Emanuel M.H., Wolterbeek R., Trimbos J.B., Jansen F.W. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol 2008, 15:466-471. (I).
148. Coccia M.E., Becattini C., Bracco G.L., Bargelli G., Scarselli G. Intraoperative ultrasound guidance for operative hysteroscopy. A prospective study. J Reprod Med 2000, 45:413-418. (II-3).
149. Bradley L.D. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol 2002, 14:409-415. (III).
150. Vilos G.A. Hysteroscopic surgery: Indication, contraindications and complications 2004, Taylor and Francis, London, (III).
151. Arieff A.I. Hyponatremia associated with permanent brain damage. Adv Intern Med 1987, 32:325-344. (II-3).
152. Ayus J.C., Wheeler J.M., Arieff A.I. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992, 117:891-897. (II-2).
153. Baggish M.S., Brill A.I., Rosensweig B., Barbot J.E., Indman P.D. Fatal acute glycine and sorbitol toxicity during operative hysteroscopy. J Gynecol Surg 1993, 9:137-143. (II-3).
154. Istre O., Bjoennes J., Naess R., Hornbaek K., Forman A. Postoperative cerebral oedema after transcervical endometrial resection and uterine irrigation with 1.5% glycine. Lancet 1994, 344:1187-1189. (II-2).
155. Taskin O., Buhur A., Birincioglu M., Burak F., Atmaca R., Yilmaz I., et al. Endometrial Na+, K+-ATPase pump function and vasopressin levels during hysteroscopic surgery in patients pretreated with GnRH agonist. J Am Assoc Gynecol Laparosc 1998, 5:119-124. (I).
156. Garry R., Hasham F., Kokri M.S., Mooney P. The effect of pressure on fluid absorption during endometrial ablation. J Gynecol Surg 1992, 8:1-10. (II-2).
157. Corson S.L., Brooks P.G., Serden S.P., Batzer F.R., Gocial B. Effects of vasopressin administration during hysteroscopic surgery. J Reprod Med 1994, 39:419-423. (I).
158. Indman P.D. Hysteroscopic treatment of submucous myomas. Clin Obstet Gynecol 2006, 49:811-820. (III).
159. Nezhat C.H., Fisher D.T., Datta S. Investigation of often-reported ten percent hysteroscopy fluid overfill: is this accurate?. J Minim Invasive Gynecol 2007, 14:489-493. (L).
160. Ayus J.C., Arieff A.I. Glycine-induced hypo-osmolar hyponatremia. Arch Intern Med 1997, 157:223-226. (II-2).
161. Phillips D.R., Milim S.J., Nathanson H.G., Phillips R.E., Haselkorn J.S. Preventing hyponatremic encephalopathy: comparison of serum sodium and osmolality during operative hysteroscopy with 5.0% mannitol and 1.5% glycine distention media. J Am Assoc Gynecol Laparosc 1997, 4:567-576. (II-1).
162. Patient death raises issue of new technology in ORs. OR Manager. 1999;15:1, 8-9 (III).
163. Vilos G.A., Brown S., Graham G., McCulloch S., Borg P. Genital tract electrical burns during hysteroscopic endometrial ablation: report of 13 cases in the United States and Canada. J Am Assoc Gynecol Laparosc 2000, 7:141-147. (III).
164. Vilos G.A., McCulloch S., Borg P., Zheng W., Denstedt J. Intended and stray radiofrequency electrical currents during resectoscopic surgery. J Am Assoc Gynecol Laparosc 2000, 7:55-63. (III).
165. Vilos G.A., Newton D.W., Odell R.C., Abu-Rafea B., Vilos A.G. Characterization and mitigation of stray radiofrequency currents during monopolar resectoscopic electrosurgery. J Minim Invasive Gynecol 2006, 13:134-140. (L).
166. Munro M.G. Mechanisms of thermal injury to the lower genital tract with radiofrequency resectoscopic surgery. J Minim Invasive Gynecol 2006, 13:36-42. (L).
167. Yang J.H., Chen M.J., Wu M.Y., Chao K.H., Ho H.N., Yang Y.S. Office hysteroscopic early lysis of intrauterine adhesion after transcervical resection of multiple apposing submucous myomas. Fertil Steril 2008, 89:1254-1259. (II-2).